Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial

Dimitrios Chanouzas, Lovesh Dyall, Peter Nightingale, Charles Ferro, Paul Moss, Matthew David Morgan, Lorraine Harper, Dimitrios Chanouzas, Lovesh Dyall, Peter Nightingale, Charles Ferro, Paul Moss, Matthew David Morgan, Lorraine Harper

Abstract

Background: The ANCA-associated vasculitides (AAV) are systemic autoimmune inflammatory disorders characterised by necrotising inflammation affecting small to medium-sized blood vessels. Despite improvements in survival, infection and cardiovascular disease remain leading causes of morbidity and mortality. Considerable evidence suggests that CD4 + CD28null T-cell expansions, predominantly seen in Cytomegalovirus (CMV) seropositive individuals, are associated with systemic dysregulation of immune function leading to a heightened risk of infection and cardiovascular disease. In patients with AAV, CD4 + CD28null expansions are driven by CMV and are associated with an increased risk of infection and mortality. The aim of this study is to explore in detail the ways in which CMV modulates the immune system and to determine whether treatment with valaciclovir blocks subclinical CMV reactivation in CMV seropositive AAV patients and ameliorates the CMV-induced adverse effects on the immune system.

Methods/design: CANVAS is a single-centre prospective open-label randomised controlled proof-of-concept trial of 50 adult CMV seropositive patients with stable AAV. Participants will be randomly allocated to receive valaciclovir orally (2 g QDS or reduced according to renal function) or no additional treatment for 6 months with an additional 6-month follow-up period. The primary outcome is the proportion of patients with CMV reactivation, as assessed by measurable viral load on quantitative blood and urine CMV polymerase chain reaction. The secondary outcomes are safety, change in the proportion of CD4+ CMV-specific T-cell population (defined as CD4 + CD28null cells) and change in soluble markers of inflammation from baseline to 6 months. Further tertiary and exploratory outcomes include persistence of the effect of valaciclovir on the proportion of CD4 + CD28null cells at 6 months post completion of treatment, change in the immune phenotype of CD4+ T cells and change in blood pressure and arterial stiffness parameters from baseline to 6 months.

Discussion: The results of this study will enable larger studies to be conducted to determine whether by controlling subclinical CMV reactivation, we can improve clinical endpoints such as infection and cardiovascular disease. The potential impact of this study is not limited to AAV, as CD4 + CD28null cells have been linked to adverse outcomes in other inflammatory conditions and in the context of an ageing immune system.

Trial registration: ClinicalTrials.gov Identifier NCT01633476 (registered 29 June 2012).

Figures

Fig. 1
Fig. 1
SPIRIT figure showing study’s schedule of enrolment, intervention and assessment. M0 baseline visit, M1 to M12 month 1 to month 12, qPCR quantitative polymerase chain reaction. *Safety blood tests will be performed only on treatment group

References

    1. Falk RJ, et al. Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. J Am Soc Nephrol. 2011;22(4):587–8. doi: 10.1681/ASN.2011010081.
    1. Jennette JC, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187–92. doi: 10.1002/art.1780370206.
    1. Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310–17. doi: 10.1136/ard.2008.088096.
    1. Mukhtyar C, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008;67(7):1004–10. doi: 10.1136/ard.2007.071936.
    1. Flossmann O, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488–94. doi: 10.1136/ard.2010.137778.
    1. Abdulahad WH, Stegeman CA, Kallenberg CG. Review article: the role of CD4+ T cells in ANCA-associated systemic vasculitis. Nephrology. 2009;14(1):26–32. doi: 10.1111/j.1440-1797.2008.01069.x.
    1. Morgan MD, et al. CD4 + CD28- T cell expansion in granulomatosis with polyangiitis (Wegener’s) is driven by latent cytomegalovirus infection and is associated with an increased risk of infection and mortality. Arthritis Rheum. 2011;63(7):2127–37. doi: 10.1002/art.30366.
    1. Trzonkowski P, et al. Immunosenescence increases the rate of acceptance of kidney allotransplants in elderly recipients through exhaustion of CD4+ T-cells. Mech Ageing Dev. 2010;131(2):96–104. doi: 10.1016/j.mad.2009.12.006.
    1. Vescovini R, et al. Intense antiextracellular adaptive immune response to human cytomegalovirus in very old subjects with impaired health and cognitive and functional status. J Immunol. 2010;184(6):3242–9. doi: 10.4049/jimmunol.0902890.
    1. Derhovanessian E, et al. Latent infection with cytomegalovirus is associated with poor memory CD4 responses to influenza A core proteins in the elderly. J Immunol. 2014;193(7):3624–31. doi: 10.4049/jimmunol.1303361.
    1. Trzonkowski P, et al. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination – an impact of immunosenescence. Vaccine. 2003;21(25–6):3826–36. doi: 10.1016/S0264-410X(03)00309-8.
    1. Walldorf J, Lubbert C. Pitfalls in diagnosis and therapy for CMV colitis in a 30-year-old HIV-positive patient. Z Gastroenterol. 2013;51(8):740–3. doi: 10.1055/s-0033-1335722.
    1. Gerli R, et al. CD4 + CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation. 2004;109(22):2744–8. doi: 10.1161/01.CIR.0000131450.66017.B3.
    1. Yadav AK, Lal A, Jha V. Cytotoxic CD4+CD28null T lymphocytes, systemic inflammation and atherosclerotic risk in patients with chronic kidney disease. Nephron Clin Pract. 2012;120(4):c185–93. doi: 10.1159/000338352.
    1. van de Berg PJ, et al. Cytomegalovirus-induced effector T cells cause endothelial cell damage. Clin Vaccine Immunol. 2012;19(5):772–9. doi: 10.1128/CVI.00011-12.
    1. Docke WD, et al. Subclinical activation of latent cytomegalovirus (CMV) infection and anti-CMV immune response in patients with atopic dermatitis. Br J Dermatol. 2003;148(5):954–63. doi: 10.1046/j.1365-2133.2003.05263.x.
    1. Ling PD, et al. The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis. 2003;187(10):1571–80. doi: 10.1086/374739.
    1. Stowe RP, et al. Chronic herpesvirus reactivation occurs in aging. Exp Gerontol. 2007;42(6):563–70. doi: 10.1016/j.exger.2007.01.005.
    1. Pourgheysari B, et al. The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire. J Virol. 2007;81(14):7759–65. doi: 10.1128/JVI.01262-06.
    1. Kannanganat S, et al. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol. 2007;81(16):8468–76. doi: 10.1128/JVI.00228-07.
    1. Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion. Immunology. 2010;129(4):474–81. doi: 10.1111/j.1365-2567.2010.03255.x.
    1. Dumitriu IE. The life (and death) of CD4 CD28 T cells in inflammatory diseases. Immunology, 2015;146(2):185–93.
    1. Reischig T, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant. 2008;8(1):69–77.
    1. Sester U, et al. PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant. 2008;8(7):1486–97. doi: 10.1111/j.1600-6143.2008.02279.x.
    1. Hickson SS, et al. Validity and repeatability of the Vicorder apparatus: a comparison with the SphygmoCor device. Hypertens Res. 2009;32(12):1079–85. doi: 10.1038/hr.2009.154.
    1. Ng KP, et al. Allopurinol is an independent determinant of improved arterial stiffness in chronic kidney disease: a cross-sectional study. PLoS One. 2014;9(3):e91961. doi: 10.1371/journal.pone.0091961.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel